On August 13, 2009, Hirokawa, Takatsugu; Takemura, Shunji; Shibazaki, Manabu; Ishiwatari, Hiroyuki published a patent.Quality Control of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde The title of the patent was 3-naphthylpyrazole compounds, histamine H4 receptor antagonists containing them, their use for treatment for inflammatory disorders, and pharmaceutical compositions containing them. And the patent contained the following:
Claimed are title compounds I [ring A = C6-10 aryl; X = (CH2)n (n = 1-6), CH:N; Y = O, S, NR8; Z = direct bond, CHR7; R1-R7 = H, halo, OH, NO2, carboxy, carbamoyl, C1-6 alkyl, C2-6 acyl, C6-10-aryl-C1-6 alkyl, C5-10-heteroaryl-C2-6 alkenyl, etc.; R8 = H, OH, C1-6 alkyloxy], their salts, or their solvates [exclusive of (E)-2-[[3-(2-Naphthyl)-1-phenyl-1H-pyrazol-4-yl]methylene]hydrazinecarboxamide] and histamine H4 receptor antagonists containing I, their salts, or their solvates. Also claimed are prophylactic and/or therapeutic agents and pharmaceutical compositions containing I, their salts, or their solvates. Thus, (S)-2-amino-N-[[3-(2-naphthyl)-1-phenyl-1H-pyrazol-4-yl]methyl]-3-phenylpropanamide at 10 μM (preparation given) showed 86% inhibition against histamine binding to human recombinant H4 receptor expressed on CHO cells. The experimental process involved the reaction of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde(cas: 36640-53-6).Quality Control of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde
The Article related to naphthylpyrazole compound preparation histamine h4 receptor antagonist inflammation inhibitor, Pharmacology: Effects Of Inflammation Inhibitors and Immune Agents and other aspects.Quality Control of 3-(Naphthalen-2-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde
Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics